

# Miquel Navasa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3894728/publications.pdf>

Version: 2024-02-01

142  
papers

16,096  
citations

27035

58  
h-index

17891

125  
g-index

151  
all docs

151  
docs citations

151  
times ranked

9598  
citing authors

#	ARTICLE	IF	CITATIONS
1	Monitoring of Donorâ€Derived Cellâ€Free DNA by Short Tandem Repeats: Concentration of Total Cellâ€Free DNA and Fragment Size for Acute Rejection Risk Assessment in Liver Transplantation. <i>Liver Transplantation</i> , 2022, 28, 257-268.	1.3	13
2	Results of a multidisciplinary strategy to improve the management of cardiovascular risk factors after liver transplantation. <i>Liver Transplantation</i> , 2022, 28, 1332-1344.	1.3	4
3	The Role of Arterial Stiffness in the Estimation of Cardiovascular Risk in Liver Transplant Recipients. <i>Transplantation Direct</i> , 2022, 8, e1272.	0.8	4
4	Everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study. <i>Revista Espanola De Enfermedades Digestivas</i> , 2022, , .	0.1	2
5	Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. <i>Journal of Hepatology</i> , 2021, 74, 148-155.	1.8	261
6	Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. <i>Journal of Hepatology</i> , 2021, 75, 1154-1163.	1.8	9
7	Trasplante hepÃ¡tico y renal en la enfermedad poliquÃ¡stica hepatorenal. <i>GastroenterologÃ­a Y HepatologÃ­a</i> , 2021, 44, 552-558.	0.2	1
8	Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance. <i>ELife</i> , 2021, 10, .	2.8	4
9	Post-Transplant Hepatocellular Carcinoma Surveillance. <i>Annals of Surgery</i> , 2021, Publish Ahead of Print, .	2.1	1
10	Incidence, Predictors, and Impact on Survival of Long-term Cardiovascular Events After Liver Transplantation. <i>Transplantation</i> , 2020, 104, 317-325.	0.5	14
11	Nuclear factor of activated T cells as potential pharmacodynamic biomarker for the risk of acute and subclinical rejection in de novo liver recipients. <i>Liver International</i> , 2020, 40, 931-946.	1.9	5
12	Active Smoking Before Liver Transplantation in Patients with Alcohol Use Disorder: Risk Factors and Outcomes. <i>Journal of Clinical Medicine</i> , 2020, 9, 2710.	1.0	4
13	MicroRNAs 155â€5p, 122â€5p, and 181aâ€5p Identify Patients With Graft Dysfunction Due to T Cellâ€Mediated Rejection After Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 1275-1286.	1.3	8
14	Kidney Graft Outcomes in High Immunological Risk Simultaneous Liverâ€Kidney Transplants. <i>Liver Transplantation</i> , 2020, 26, 517-527.	1.3	11
15	Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 72, 1267-1282.	3.6	37
16	Original and generic preservation solutions in organ transplantation. A new paradigm?. <i>Acta Cirurgica Brasileira</i> , 2020, 35, e202000101.	0.3	2
17	The challenge of chronic hepatitis E in liver transplant recipients: Failure of sofosbuvir plus ribavirin therapy. <i>GastroenterologÃ­a Y HepatologÃ­a</i> , 2020, 43, 136-137.	0.2	6
18	Prediction of Alcohol Relapse Among Liver Transplant Candidates With Less Than 6 Months of Abstinence Using the Highâ€Risk Alcoholism Relapse Score. <i>Liver Transplantation</i> , 2019, 25, 1142-1154.	1.3	20

#	ARTICLE	IF	CITATIONS
19	Torque Tenó Virus Is Associated With the State of Immune Suppression Early After Liver Transplantation. <i>Liver Transplantation</i> , 2019, 25, 302-310.	1.3	38
20	Hepatitis C virus intrinsic molecular determinants may contribute to the development of cholestatic hepatitis after liver transplantation. <i>Journal of General Virology</i> , 2019, 100, 63-68.	1.3	1
21	The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. <i>Journal of Hepatology</i> , 2018, 69, 11-17.	1.8	80
22	Viral eradication and fibrosis resolution in post-liver transplant cholestatic hepatitis C virus. <i>Liver Transplantation</i> , 2018, 24, 703-707.	1.3	5
23	Heparin but not tissue plasminogen activator improves outcomes in donation after circulatory death liver transplantation in a porcine model. <i>Liver Transplantation</i> , 2018, 24, 665-676.	1.3	15
24	Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. <i>Hepatology</i> , 2018, 67, 1683-1694.	3.6	114
25	Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. <i>Journal of Hepatology</i> , 2018, 69, 1250-1259.	1.8	152
26	Increased risk of portal vein thrombosis in patients with autoimmune hepatitis on the liver transplantation waiting list. <i>Clinical Transplantation</i> , 2017, 31, e13001.	0.8	7
27	A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients. <i>Scientific Reports</i> , 2017, 7, 10497.	1.6	23
28	Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients. <i>World Journal of Gastroenterology</i> , 2017, 23, 3163.	1.4	23
29	Delta-MELD and survival after liver transplantation: the slope matters. <i>Liver International</i> , 2016, 36, 949-951.	1.9	1
30	Simple prediction of long-term clinical outcomes in patients with mild hepatitis C recurrence after liver transplantation. <i>Transplant International</i> , 2016, 29, 698-706.	0.8	5
31	Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. <i>Hepatology</i> , 2016, 63, 839-849.	3.6	101
32	Liver transplantation in Spain. <i>Liver Transplantation</i> , 2016, 22, 1259-1264.	1.3	22
33	Usefulness of liver stiffness measurement during acute cellular rejection in liver transplantation. <i>Liver Transplantation</i> , 2016, 22, 298-304.	1.3	32
34	Rapidity of fibrosis progression in liver transplant recipients with recurrent hepatitis C is influenced by toll-like receptor 3 polymorphism. <i>Clinical Transplantation</i> , 2016, 30, 810-818.	0.8	8
35	Metabolic Characterization of Advanced Liver Fibrosis in HCV Patients as Studied by Serum 1H-NMR Spectroscopy. <i>PLoS ONE</i> , 2016, 11, e0155094.	1.1	44
36	Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C. <i>Annals of Hepatology</i> , 2016, 15, 512-23.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Severity of Liver Disease Affects HCV Kinetics in Patients Treated with Intravenous Silibinin Monotherapy. <i>Antiviral Therapy</i> , 2015, 20, 149-155.	0.6	14
38	Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes. <i>Liver Transplantation</i> , 2015, 21, 1347-1354.	1.3	48
39	Protective Effect of Intravenous High Molecular Weight Polyethylene Glycol on Fatty Liver Preservation. <i>BioMed Research International</i> , 2015, 2015, 1-10.	0.9	17
40	HEV infection in two referral centers in Spain; epidemiology and clinical outcomes. <i>Journal of Clinical Virology</i> , 2015, 63, 76-80.	1.6	21
41	<i>Candida norvegensis</i> fungemia in a liver transplant recipient. <i>Revista Iberoamericana De Micologia</i> , 2015, 32, 115-117.	0.4	9
42	Lack of a 5.9 kDa Peptide C-Terminal Fragment of Fibrinogen $\alpha_2$ Chain Precedes Fibrosis Progression in Patients with Liver Disease. <i>PLoS ONE</i> , 2014, 9, e109254.	1.1	12
43	Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. <i>Journal of Hepatology</i> , 2014, 61, S120-S131.	1.8	65
44	Graft and viral outcomes in retransplantation for hepatitis C virus recurrence and <sc>HCV</sc> primary liver transplantation: a caseâ€“control study. <i>Clinical Transplantation</i> , 2014, 28, 821-828.	0.8	8
45	HCV-Induced Immune Responses Influence the Development of Operational Tolerance After Liver Transplantation in Humans. <i>Science Translational Medicine</i> , 2014, 6, 242ra81.	5.8	74
46	Early periportal sinusoidal fibrosis is an accurate marker of accelerated HCV recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2014, 61, 270-277.	1.8	11
47	IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation. <i>Journal of Clinical Virology</i> , 2014, 61, 282-285.	1.6	4
48	Genetic variants of innate immune receptors and infections after liver transplantation. <i>World Journal of Gastroenterology</i> , 2014, 20, 11116.	1.4	9
49	Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. <i>Journal of Gastroenterology</i> , 2013, 48, 762-769.	2.3	19
50	Incidence and outcome of early <i>Candida</i> peritonitis after liver and pancreas transplantation. <i>Mycoses</i> , 2013, 56, 162-167.	1.8	11
51	Imaging of hepatitis C virus infection in liver grafts after liver transplantation. <i>Journal of Hepatology</i> , 2013, 59, 271-278.	1.8	10
52	Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. <i>Journal of Hepatology</i> , 2013, 58, 415-420.	1.8	49
53	Bone Disease in Patients Awaiting Liver Transplantation. Has the Situation Improved in the Last Two Decades?. <i>Calcified Tissue International</i> , 2013, 93, 571-576.	1.5	19
54	Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation. <i>Journal of Hepatology</i> , 2012, 56, 355-358.	1.8	19

#	ARTICLE	IF	CITATIONS
55	ARFI, FibroScan® <sup>®</sup> , ELF, and their combinations in the assessment of liver fibrosis: A prospective study. <i>Journal of Hepatology</i> , 2012, 57, 281-287.	1.8	150
56	Viral Hepatitis in Liver Transplantation. <i>Gastroenterology</i> , 2012, 142, 1373-1383.e1.	0.6	176
57	Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites. <i>Digestive and Liver Disease</i> , 2012, 44, 239-244.	0.4	17
58	Effects of Graft Quality on Non-urgent Liver Retransplantation Survival: Should We Avoid High-Risk Donors?. <i>World Journal of Surgery</i> , 2012, 36, 2914-2922.	0.8	13
59	Interplay between Basic Residues of Hepatitis C Virus Glycoprotein E2 with Viral Receptors, Neutralizing Antibodies and Lipoproteins. <i>PLoS ONE</i> , 2012, 7, e52651.	1.1	18
60	A Gaussia Luciferase Cell-Based System to Assess the Infection of Cell Culture- and Serum-Derived Hepatitis C Virus. <i>PLoS ONE</i> , 2012, 7, e53254.	1.1	7
61	Hepatic encephalopathy and post-transplant hyponatremia predict early calcineurin inhibitor-induced neurotoxicity after liver transplantation. <i>Transplant International</i> , 2011, 24, 812-819.	0.8	42
62	Noninvasive assessment of liver fibrosis. <i>Hepatology</i> , 2011, 53, 325-335.	3.6	365
63	Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. <i>Hepatology</i> , 2010, 51, 23-34.	3.6	120
64	Multifaceted perspective of the waiting list for liver transplantation: The value of pharmacokinetic models. <i>Hepatology</i> , 2010, 51, 12-15.	3.6	25
65	Severe acute hepatitis in the dress syndrome: Report of two cases. <i>Annals of Hepatology</i> , 2010, 9, 198-201.	0.6	34
66	Serum Fibrosis Markers Identify Patients With Mild and Progressive Hepatitis C Recurrence After Liver Transplantation. <i>Gastroenterology</i> , 2010, 138, 147-158.e1.	0.6	68
67	Retransplantation in patients with hepatitis C recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2010, 53, 962-970.	1.8	61
68	Clinically relevant differences in the model for end-stage liver disease and model for end-stage liver disease-sodium scores determined at three university-based laboratories of the same area. <i>Liver Transplantation</i> , 2009, 15, 300-305.	1.3	18
69	Donor mannose-binding lectin gene polymorphisms influence the outcome of liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 1217-1224.	1.3	47
70	Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. <i>Transplant International</i> , 2009, 22, 198-206.	0.8	47
71	Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. <i>Journal of Hepatology</i> , 2009, 50, 719-728.	1.8	184
72	Antiviral therapy in HCV-infected cirrhotic patients awaiting liver transplantation. <i>Journal of Hepatology</i> , 2009, 51, 960-962.	1.8	1

#	ARTICLE	IF	CITATIONS
73	How accurately and how early can we predict rapid fibrosis progression in hepatitis C virus-infected patients after liver transplantation?. <i>Liver Transplantation</i> , 2008, 14, 1237-1239.	1.3	3
74	Immune reconstitution syndrome after voriconazole treatment for cryptococcal meningitis in a liver transplant recipient. <i>Liver Transplantation</i> , 2008, 14, 1671-1674.	1.3	24
75	Optimization of liver grafts in liver retransplantation: A European single-center experience. <i>Surgery</i> , 2008, 144, 762-769.	1.0	41
76	MR Elastography to Assess Liver Fibrosis. <i>Radiology</i> , 2008, 247, 591-592.	3.6	12
77	Antiviral therapy in HCV decompensated cirrhosis: To treat or not to treat?. <i>Journal of Hepatology</i> , 2007, 46, 185-188.	1.8	13
78	Efficacy of Antiviral Therapy on Hepatitis C Recurrence After Liver Transplantation: A Randomized Controlled Study. <i>Gastroenterology</i> , 2007, 132, 1746-1756.	0.6	332
79	Primary Prophylaxis of Spontaneous Bacterial Peritonitis Delays Hepatorenal Syndrome and Improves Survival in Cirrhosis. <i>Gastroenterology</i> , 2007, 133, 818-824.	0.6	639
80	Noninvasive tests in the post-liver transplantation setting. <i>Liver Transplantation</i> , 2007, 13, 628-629.	1.3	1
81	Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease. <i>Liver International</i> , 2007, 27, 492-497.	1.9	27
82	Hyponatremia Impairs Early Posttransplantation Outcome in Patients With Cirrhosis Undergoing Liver Transplantation. <i>Gastroenterology</i> , 2006, 130, 1135-1143.	0.6	179
83	Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. <i>Hepatology</i> , 2006, 43, 492-499.	3.6	282
84	Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. <i>Liver Transplantation</i> , 2006, 12, 1791-1798.	1.3	379
85	Sustained low diffusing capacity in hepatopulmonary syndrome after liver transplantation. <i>World Journal of Gastroenterology</i> , 2006, 12, 5878.	1.4	33
86	Performance of Hepatitis C Virus Core Antigen Immunoassay in Monitoring Viral Load after Liver Transplantation. <i>Transplantation</i> , 2005, 79, 1441-1444.	0.5	6
87	Nosocomial transmission of HCV in the liver unit of a tertiary care center. <i>Hepatology</i> , 2005, 41, 115-122.	3.6	55
88	Applicability of adult-to-adult living donor liver transplantation. <i>Journal of Hepatology</i> , 2005, 43, 104-109.	1.8	30
89	Renal Failure in Patients With Cirrhosis and Sepsis Unrelated to Spontaneous Bacterial Peritonitis: Value of MELD Score. <i>Gastroenterology</i> , 2005, 129, 1944-1953.	0.6	232
90	Treatment of HCV infection in patients with advanced cirrhosis. <i>Hepatology</i> , 2004, 40, 498-498.	3.6	21

#	ARTICLE	IF	CITATIONS
91	Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. <i>Hepatology</i> , 2004, 40, 699-707.	3.6	189
92	Gas exchange mechanism of orthodeoxia in hepatopulmonary syndrome. <i>Hepatology</i> , 2004, 40, 660-666.	3.6	144
93	High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: An indication for salvage liver transplantation. <i>Liver Transplantation</i> , 2004, 10, 1294-1300.	1.3	263
94	Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. <i>Journal of Hepatology</i> , 2004, 40, 140-146.	1.8	203
95	Beneficial Effect of Angiotensin-Blocking Agents on Graft Fibrosis in Hepatitis C Recurrence after Liver Transplantation. <i>Transplantation</i> , 2004, 78, 686-691.	0.5	82
96	Applicability of liver transplantation in Catalonia at the end of the millennium. A prospective study of adult patient selection for liver transplantation. <i>Transplant International</i> , 2003, 16, 270-275.	0.8	7
97	Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. <i>Journal of Hepatology</i> , 2003, 39, 389-396.	1.8	291
98	Acute cellular rejection in liver transplant recipients under cyclosporine immunosuppression: predictive factors of response to antirejection therapy. <i>Transplantation</i> , 2002, 73, 1936-1943.	0.5	23
99	Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. <i>Transplantation</i> , 2002, 74, 1381-1386.	0.5	89
100	Failure of <i>Lactobacillus</i> spp. to prevent bacterial translocation in a rat model of experimental cirrhosis. <i>Journal of Hepatology</i> , 2002, 36, 501-506.	1.8	103
101	Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis. <i>Hepatology</i> , 2002, 35, 140-148.	3.6	788
102	Hepatitis C virus kinetics during and immediately after liver transplantation. <i>Hepatology</i> , 2002, 35, 680-687.	3.6	467
103	Diagnosis, treatment and prevention of spontaneous bacterial peritonitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2000, 14, 975-990.	1.0	38
104	Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. <i>Journal of Hepatology</i> , 2000, 33, 43-48.	1.8	381
105	Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. <i>Journal of Hepatology</i> , 2000, 32, 142-153.	1.8	838
106	Prevalence and prognostic value of hepatocellular carcinoma in cirrhotic patients presenting with spontaneous bacterial peritonitis. <i>Journal of Hepatology</i> , 2000, 33, 423-429.	1.8	29
107	Hepatopulmonary syndrome associated with cardiorespiratory disease. <i>Journal of Hepatology</i> , 1999, 30, 882-889.	1.8	103
108	Prognostic significance of hepatic encephalopathy in patients with cirrhosis. <i>Journal of Hepatology</i> , 1999, 30, 890-895.	1.8	500

#	ARTICLE	IF	CITATIONS
109	Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis. <i>New England Journal of Medicine</i> , 1999, 341, 403-409.	13.9	1,519
110	In-111 Octreotide Scan in a Case of a Neuroendocrine Tumor of Unknown Origin. <i>Clinical Nuclear Medicine</i> , 1999, 24, 955.	0.7	10
111	Liver transplantation for small hepatocellular carcinoma: The tumor-node-metastasis classification does not have prognostic power. <i>Hepatology</i> , 1998, 27, 1572-1577.	3.6	357
112	Antibiotic prophylaxis for spontaneous bacterial peritonitis: how and whom?. <i>Journal of Hepatology</i> , 1998, 29, 490-494.	1.8	31
113	Liver transplantation in patients with non-biliary cirrhosis: prognostic value of preoperative factors. <i>Journal of Hepatology</i> , 1998, 28, 320-328.	1.8	21
114	Bacterial Infections in Liver Disease. <i>Seminars in Liver Disease</i> , 1997, 17, 323-333.	1.8	133
115	Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. <i>Journal of Hepatology</i> , 1997, 26, 88-95.	1.8	109
116	Quality of life, major medical complications and hospital service utilization in patients with primary biliary cirrhosis after liver transplantation. <i>Journal of Hepatology</i> , 1996, 25, 129-134.	1.8	54
117	Diabetes mellitus after liver transplantation: prevalence and predictive factors. <i>Journal of Hepatology</i> , 1996, 25, 64-71.	1.8	152
118	Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study. <i>Hepatology</i> , 1995, 21, 674-679.	3.6	171
119	Experience with cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 1995, 22, 141-145.	0.8	21
120	Increased plasma endothelin in cirrhosis. Relationship with systemic endotoxemia and response to changes in effective blood volume. <i>Journal of Hepatology</i> , 1995, 22, 389-398.	1.8	49
121	Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis. <i>Hepatology</i> , 1994, 20, 1495-1501.	3.6	526
122	Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1994, 21, 24-28.	1.8	36
123	Spontaneous bacterial peritonitis in cirrhosis: Predictive factors of infection resolution and survival in patients treated with cefotaxime. <i>Hepatology</i> , 1993, 17, 251-257.	3.6	215
124	Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. <i>Hepatology</i> , 1993, 17, 355-360.	3.6	183
125	Treatment of small hepatocellular carcinoma in cirrhotic patients: A cohort study comparing surgical resection and percutaneous ethanol injection. <i>Hepatology</i> , 1993, 18, 1121-1126.	3.6	305
126	Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. <i>Gastroenterology</i> , 1993, 105, 229-236.	0.6	820



#	ARTICLE	IF	CITATIONS
127	Liver transplantation for acute liver failure: Analysis of applicability. <i>Gastroenterology</i> , 1993, 105, 532-538.	0.6	80
128	Spontaneous bacterial peritonitis in cirrhosis: Predictive factors of infection resolution and survival in patients treated with cefotaxime. <i>Hepatology</i> , 1993, 17, 251-257.	3.6	15
129	Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: Relevance of ascitic fluid protein concentration. <i>Hepatology</i> , 1992, 16, 724-727.	3.6	204
130	Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. <i>Hepatology</i> , 1990, 11, 230-238.	3.6	172
131	Hemodynamic effects of glucagon in portal hypertension. <i>Hepatology</i> , 1990, 11, 668-673.	3.6	70
132	Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: A placebo-controlled clinical trial. <i>Hepatology</i> , 1989, 10, 962-968.	3.6	121
133	Endoscopic measurement of variceal pressure in cirrhosis: Correlation with portal pressure and variceal hemorrhage. <i>Gastroenterology</i> , 1989, 96, 873-880.	0.6	82
134	Endoscopic Measurement of Variceal Pressure in Cirrhosis: Correlation With Portal Pressure and Variceal Hemorrhage. <i>Gastroenterology</i> , 1989, 96, 873-880.	0.6	154
135	Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. <i>Gastroenterology</i> , 1989, 96, 1110-1118.	0.6	153
136	Atrial natriuretic factor in cirrhosis with ascites: Plasma levels, cardiac release and splanchnic extraction. <i>Hepatology</i> , 1988, 8, 636-642.	3.6	170
137	Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension. <i>Hepatology</i> , 1988, 8, 850-854.	3.6	86
138	Effects of vasopressin on the intravariceal pressure in patients with cirrhosis: Comparison with the effects on portal pressure. <i>Hepatology</i> , 1988, 8, 861-865.	3.6	78
139	Hyperglucagonism and glucagon resistance in cirrhosis. <i>Journal of Hepatology</i> , 1988, 6, 325-331.	1.8	21
140	Effects of Somatostatin in Patients with Portal Hypertension. <i>Hormone Research</i> , 1988, 29, 99-102.	1.8	27
141	Steady-State Extrarenal Sorbitol Clearance as a Measure of Hepatic Plasma Flow. <i>Gastroenterology</i> , 1988, 95, 749-759.	0.6	100
142	Portal hypertension in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1987, 5, 292-298.	1.8	96